SEC Form 4 · accession 0001193125-26-294478
Beam Therapeutics Inc. · BEAM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Amy Simon
Officer — Chief Medical Officer
Period of report
Jun 30, 2026
Accepted (ET)
Jul 2, 2026 · 4:05 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001745999
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 30, 2026 | S | 373 | $34.73 | D | 102,363 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan on June 30, 2022. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023.